Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 17/20 | 0.68 |
| ▸ | CA9 | Q16790 | 16/20 | 0.68 |
| ▸ | ELANE | P08246 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 6/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834902 | 0.81 | CA12 (1.00) | CA12CA9ELANECA2CA1 | |
| SCHEMBL1101896 | 0.81 | CA12 (1.00) | CA12CA9ELANECA2CA1 | |
| SCHEMBL6958970 | 0.79 | CA12 (0.71) | CA12CA9ELANECA2CA1 | |
| SCHEMBL698407 | 0.78 | CA9 (1.00) | CA12CA9ELANECA2 | |
| SCHEMBL5899155 | 0.77 | ELANE (1.00) | CA12CA9ELANECA2CA1 | |
| SCHEMBL8865776 | 0.77 | CA12 (0.69) | CA12CA9ELANECA2CA1 | |
| SCHEMBL7290946 | 0.77 | CA12 (0.69) | CA12CA9ELANECA2CA1 | |
| SCHEMBL7281348 | 0.77 | CA12 (0.69) | CA12CA9ELANECA2CA1 | |
| SCHEMBL356403 | 0.77 | CA12 (0.69) | CA12CA9ELANECA2 | |
| SCHEMBL7290973 | 0.77 | CA12 (0.69) | CA12CA9ELANECA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | NQO1, TXN2, MPO | CA12 4729/4885CA9 4167/4885ELANE 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.